Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is one of the most common types of T-cell lymphoma, representing about 15–20% of cases of peripheral T-cell lymphoma (PTCL). It is characterized by a unique clinical presentation and distinct pathologic and molecular features. Classes of drugs particularly active in AITL are emerging; however, treatment of relapsed and refractory disease remains a challenge. This chapter reviews the epidemiology, clinical presentation, pathogenesis, diagnosis, and treatment of AITL.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Frizzera G, Moran EM, Rappaport H (1974) Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1:1070–1073
Lukes RJ, Tindle BH (1975) Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin’s disease. New Engl J Med 292:1–8
Lennert K (1979) Nature, prognosis and nomenclature of angioimmunoblastic (lymphadenopathy (lymphogranulomatosis X or T-zone lymphoma). Deutsche medizinische Wochenschrift 104:1246–1247
Feller AC, Griesser H, Schilling CV, Wacker HH, Dallenbach F, Bartels H, Kuse R, Mak TW, Lennert K (1988) Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy. Am J Pathol 133:549–556
Kaneko Y, Maseki N, Sakurai M, Takayama S, Nanba K, Kikuchi M, Frizzera G (1988) Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive “angioimmunoblastic lymphadenopathy with dysproteinemia-type” features. Blood 72:413–421
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the international Lymphoma study group. Blood 84:1361–1392
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J (2000) Lymphoma classification—from controversy to consensus: the R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol 11(Suppl 1):3–10
Vose J, Armitage J, Weisenburger D (2008) International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130
Mourad N, Mounier N, Briere J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, Diebold J, Haioun C, Coiffier B, Gisselbrecht C, Gaulard P (2008) Groupe d’Etude des Lymphomes de lA. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 111:4463–4470
Cho YU, Chi HS, Park CJ, Jang S, Seo EJ, Huh J (2009) Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement. Am J Clin Pathol 131:640–646
de Leval L, Gisselbrecht C, Gaulard P (2010) Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 148:673–689
Singh A, Schabath R, Ratei R, Stroux A, Klemke CD, Nebe T, Florcken A, van Lessen A, Anagnostopoulos I, Dorken B, Ludwig WD, Pezzutto A, Westermann J (2014) Peripheral blood sCD3(−) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematol Oncol 32:16–21
Willenbrock K, Brauninger A, Hansmann ML (2007) Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol 138:733–739
de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, Lamant L, Leroy K, Briere J, Molina T, Berger F, Gisselbrecht C, Xerri L, Gaulard P (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:4952–4963
Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A (2005) Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood 106:1501–1502
Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, Forster R (2000) Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 192:1545–1552
Cortes JR, Palomero T (2016) The curious origins of angioimmunoblastic T-cell lymphoma. Curr Opin Hematol 23:434–443
Ueno H, Banchereau J, Vinuesa CG (2015) Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol 16:142–152
Vinuesa CG, Linterman MA, Yu D, MacLennan IC (2016) Follicular helper T cells. Annu Rev Immunol 34:335–368
Leavenworth JW, Verbinnen B, Yin J, Huang H, Cantor H (2015) A p85alpha-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Nat Immunol 16:96–106
Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, Matskevitch TD, Wang YH, Dong C (2009) Bcl6 mediates the development of T follicular helper cells. Science 325:1001–1005
Couronne L, Bastard C, Bernard OA (2012) TET2 and DNMT3A mutations in human T-cell lymphoma. New Engl J Med 366:95–96
Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM (2014) A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123:1293–1296
Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y, Sakata S, Kamada Y, Nakamoto-Matsubara R, Tran NB, Izutsu K, Sato Y, Ohta Y, Furuta J, Shimizu S, Komeno T, Sato Y, Ito T, Noguchi M, Noguchi E, Sanada M, Chiba K, Tanaka H, Suzukawa K, Nanmoku T, Hasegawa Y, Nureki O, Miyano S, Nakamura N, Takeuchi K, Ogawa S, Chiba S (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46:171–175
Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat G, Piris MA, Campo E, Bernard OA, Rabadan R, Ferrando AA (2014) Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46:166–170
Jaffe AB, Hall A (2005) Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21:247–269
Henning SW, Galandrini R, Hall A, Cantrell DA (1997) The GTPase Rho has a critical regulatory role in thymus development. EMBO J 16:2397–2407
Pernis AB (2009) Rho GTPase-mediated pathways in mature CD4+ T cells. Autoimmun Rev 8:199–203
Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, Kim SC, Lee B, Rho K, Lee JE, Cho KH, Kim W, Ju H, Kim J, Kim SJ, Kim WS, Lee S, Ko YH (2014) A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 46:371–375
Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, Totoki Y, Kataoka TR, Hirata M, Aoki K, Nakano K, Kitanaka A, Sakata-Yanagimoto M, Egami S, Shiraishi Y, Chiba K, Tanaka H, Shiozawa Y, Yoshizato T, Suzuki H, Kon A, Yoshida K, Sato Y, Sato-Otsubo A, Sanada M, Munakata W, Nakamura H, Hama N, Miyano S, Nureki O, Shibata T, Haga H, Shimoda K, Katada T, Chiba S, Watanabe T, Ogawa S (2016) Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood 127:596–604
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127:2375–2390
Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, Parrens M, Martin A, Xerri L, Brousset P, Chan LC, Chan WC, Gaulard P, Mak TW (2012) IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119:1901–1903
Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839–843
Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144–147
Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, Steidl C, Fu K, Li Y, Hung S, Weisenburger DD, Greiner TC, Smith L, Ott G, Rogan EG, Staudt LM, Vose J, Iqbal J, Chan WC (2015) IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 126:1741–1752
Muto H, Sakata-Yanagimoto M, Nagae G, Shiozawa Y, Miyake Y, Yoshida K, Enami T, Kamada Y, Kato T, Uchida K, Nanmoku T, Obara N, Suzukawa K, Sanada M, Nakamura N, Aburatani H, Ogawa S, Chiba S (2014) Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J 4:e264
Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, Thompson CB (2013) The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 288:3804–3815
Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, Spath D, Kayser S, Zucknick M, Gotze K, Horst HA, Germing U, Dohner H, Dohner K (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol Official J Am Soc Clin Oncol 28:3636–3643
Scourzic L, Couronne L, Pedersen MT, Della Valle V, Diop M, Mylonas E, Calvo J, Mouly E, Lopez CK, Martin N, Fontenay M, Bender A, Guibert S, Dubreuil P, Dessen P, Droin N, Pflumio F, Weber M, Gaulard P, Helin K, Mercher T, Bernard OA (2016) DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia 30:1388–1398
Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, Simone PD, Zhang W, Gong Q, Wang C, Cannon A, Heavican T, Mottok A, Hung S, Rosenwald A, Gascoyne R, Fu K, Greiner TC, Weisenburger DD, Vose JM, Staudt LM, Xiao W, Borgstahl GE, Davis S, Steidl C, McKeithan T, Iqbal J, Chan WC (2016) Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia 30:1062–1070
Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M, Iwaszkiewicz J, Fataccioli V, Bisig B, Roberti A, Grewal J, Bruneau J, Fabiani B, Martin A, Bonnet C, Michielin O, Jais JP, Figeac M, Bernard OA, Delorenzi M, Haioun C, Tournilhac O, Thome M, Gascoyne RD, Gaulard P, de Leval L (2016) Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128:1490–1502
Yoo HY, Kim P, Kim WS, Lee SH, Kim S, Kang SY, Jang HY, Lee JE, Kim J, Kim SJ, Ko YH, Lee S (2016) Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica 101:757–763
Palacios EH, Weiss A (2004) Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23:7990–8000
Attygalle AD, Feldman AL, Dogan A (2013) ITK/SYK translocation in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 37:1456–1457
Vaque JP, Gomez-Lopez G, Monsalvez V, Varela I, Martinez N, Perez C, Dominguez O, Grana O, Rodriguez-Peralto JL, Rodriguez-Pinilla SM, Gonzalez-Vela C, Rubio-Camarillo M, Martin-Sanchez E, Pisano DG, Papadavid E, Papadaki T, Requena L, Garcia-Marco JA, Mendez M, Provencio M, Hospital M, Suarez-Massa D, Postigo C, San Segundo D, Lopez-Hoyos M, Ortiz-Romero PL, Piris MA, Sanchez-Beato M (2014) PLCG1 mutations in cutaneous T-cell lymphomas. Blood 123:2034–2043
Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G (2014) A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet 46:844–849
Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, Gazzola A, Gloghini A, Righi S, Rossi M, Tagliafico E, Zinzani PL, Zupo S, Baccarani M, Pileri SA (2007) Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Can Res 67:10703–10710
Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legres L, Meignin V, Oksenhendler E, Maignin CL, Calvo F, Briere J, Gisselbrecht C, Janin A (2004) Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest J Tech Methods Pathol 84:1512–1519
Konstantinou K, Yamamoto K, Ishibashi F, Mizoguchi Y, Kurata M, Nakagawa Y, Suzuki K, Sawabe M, Ohta M, Miyakoshi S, Crawley JT, Kitagawa M (2009) Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol 144:696–704
Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM (2014) Lymphoma Leukemia molecular profiling P, the international peripheral TcLP. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915–2923
Rho R, Laddis T, McQuain C, Selves J, Woda B, Knecht H (1996) Miliary tuberculosis in a patient with Epstein-Barr virus-associated angioimmunoblastic lymphadenopathy. Ann Hematol 72:333–335
Konig M, Grunder K, Nilles M, Schill WB (1991) Cutaneous cryptococcosis as the first symptom of a disseminated cryptococcosis in a patient with lymphogranulomatosis X. Mycoses 34:309–311
Luppi M, Torelli G (1996) The new lymphotropic herpesviruses (HHV-6, HHV-7, HHV-8) and hepatitis C virus (HCV) in human lymphoproliferative diseases: an overview. Haematologica 81:265–281
Helm TN, Steck WD, Proffitt MR, Bergfeld WF, Tubbs RR, Lo J (1990) Kaposi’s sarcoma, angioimmunoblastic lymphadenopathy, and antibody to HIV-1 p24 antigen in a patient nonreactive for HIV-1 with use of ELISA. J Am Acad Dermatol 23:317–318
Anagnostopoulos I, Hummel M, Finn T, Tiemann M, Korbjuhn P, Dimmler C, Gatter K, Dallenbach F, Parwaresch MR, Stein H (1992) Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 80:1804–1812
Brauninger A, Spieker T, Willenbrock K, Gaulard P, Wacker HH, Rajewsky K, Hansmann ML, Kuppers R (2001) Survival and clonal expansion of mutating “forbidden” (immunoglobulin receptor-deficient) epstein-barr virus-infected b cells in angioimmunoblastic t cell lymphoma. J Exp Med 194:927–940
Zhou Y, Attygalle AD, Chuang SS, Diss T, Ye H, Liu H, Hamoudi RA, Munson P, Bacon CM, Dogan A, Du MQ (2007) Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 138:44–53
Dogan A, Attygalle AD, Kyriakou C (2003) Angioimmunoblastic T-cell lymphoma. Br J Haematol 121:681–691
Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC, Chuang SS, Cabecadas J, Isaacson PG, Du MQ, Gaulard P, Dogan A (2007) Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol 31:1077–1088
Balague O, Martinez A, Colomo L, Rosello E, Garcia A, Martinez-Bernal M, Palacin A, Fu K, Weisenburger D, Colomer D, Burke JS, Warnke RA, Campo E (2007) Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. Am J Surg Pathol 31:1310–1322
Dogan A, Gaulard P, Jaffe ES, Ralfkiaer E, Müller-Hermelink HK (2008) Angioimmunoblastic T-cell Lymphoma. In: WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC, pp 309–311
Dorfman DM, Shahsafaei A (2011) CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 35:76–83
Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, Isaacson PG, Dogan A (2002) Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 99:627–633
Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, Zinzani PL, Pileri SA (2013) CD30 expression in peripheral T-cell lymphomas. Haematologica 98:e81–2
Stacchini A, Demurtas A, Aliberti S, Francia di Celle P, Godio L, Palestro G, Novero D (2007) The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas. Am J Clin Pathol 128:854–864
Serke S, van Lessen A, Hummel M, Szczepek A, Huhn D, Stein H (2000) Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma. Cytometry 42:180–187
Schlegelberger B, Zhang Y, Weber-Matthiesen K, Grote W (1994) Detection of aberrant clones in nearly all cases of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined interphase and metaphase cytogenetics. Blood 84:2640–2648
Thorns C, Bastian B, Pinkel D, Roydasgupta R, Fridlyand J, Merz H, Krokowski M, Bernd HW, Feller AC (2007) Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach. Genes Chromosom Cancer 46:37–44
Ruiz SJ, Cotta CV (2015) Follicular helper T-cell lymphoma: a B-cell-rich variant of T-cell lymphoma. Annals Diag Pathol 19:187–192
Hu S, Young KH, Konoplev SN, Medeiros LJ (2012) Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas. Hum Pathol 43:1789–1798
Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, Martin-Garcia N, Copie-Bergman C, Gaillard F, Qubaja M, Fabiani B, Roncador G, Haioun C, Delfau-Larue MH, Marafioti T, Chott A, Gaulard P (2009) Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol 33:682–690
Moskowitz AJ, Lunning MA, Horwitz SM (2014) How I treat the peripheral T-cell lymphomas. Blood 123:2636–2644
Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, Engert A, Einsele H, Muller-Hermelink HK, Wilhelm M (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-Cell Lymphomas: results of a prospective multicenter study. J Clin Oncol Official J Am Soc Clin Oncol 27:106–113
Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 2010;151:159-66
International T-Cell Lymphoma Project (2008) International peripheral T-Cell and natural killer/T-Cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130
Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM (2004) Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15:1467–1475
Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma study group. Blood 116:3418–3425
Ellin F, Landstrom J, Jerkeman M, Relander T (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma registry. Blood 124:1570–1577
d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Osterborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Ostenstad B, Fagerli UM, Gadeberg OV, Sundstrom C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol Official J Am Soc Clin Oncol 30:3093–3099
Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, Zelenetz A, Matasar MJ, Sauter C, Goldberg J, Horwitz SM (2013) A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk 13:664–670
Mehta-Shah N, Ito K, Bantilan KS, Moskowitz AJ, Sauter CS, Horwitz SM, Schoder H (2016) Interim PET evaluation by deauville criteria is an effective risk stratification tool in PTCL. Blood 128:186
Lunning MA, Moskowitz AJ, Horwitz S (2013) Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve. J Clin Oncol 31:1922–1927
Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M (2008) Societe Francaise de Greffe de Moelle et de Therapie C. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26:2264–2271
Mehta-Shah N, Lunning MA, Ruan J, Nair S, Boruchov AM, Moskowitz AJ, Gerecitano JF, Hamlin PA, Leonard JP, Lynch P, Matasar MJ, Moskowitz C, Portlock C, Younes A, Myskowski P, Nolan P, Palomba ML, Vredenburgh J, Querfeld C, Straus DJ, Zelenetz A, Schroder H, Rademaker J, Schaffer W, Horwitz SM (2015) A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma. Hematol Oncol 33 (Supplement 1)
Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, Armand P, Alyea EP, Freedman AS, Soiffer RJ, Antin JH (2011) A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 22:1608–1613
Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M, Sobecks R, Andresen S, Hsi ED, Pohlman B, Sweetenham JW (2007) Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transp 40:239–243
Horwitz SMC, Kewalramani T, Hamlin P, Straus D, O’Connor O, Noy A, Portlock C, Nimer S, Palomba L, Zelenetz A (2005) Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat. Blood (ASH Annual Meeting Abstracts) 106, abstract 2679
Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN (2013) Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma. J Clin Oncol Official J Am Soc Clin Oncol 31:3100–3109
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30:631–636
O’Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A (2015) Belinostat in patients with relapsed or refractory peripheral T-Cell Lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33:2492–2499
O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29:1182–1189
Dupuis J, Morschhauser F, Ghesquieres H, Tilly H, Casasnovas O, Amorim S, Ribrag V, Coiffier B (2014) Final Analysis of the RO-CHOP Phase Ib/II Study: romidepsin in association with CHOP in patients with peripheral T-Cell Lymphoma (PTCL). Blood (ASH Annual Meeting Abstracts) 124:504
Mehta-Shah N, Moskowitz AJ, Lunning M, Lynch P, Scheuerman M, Kumar A, Gerecitano JF, Zelenetz AD, Hamlin PA, Noy A, Matasar MJ, Palomba ML, Younes A, Schaffer W, Grewal R, Rademaker J, Sauter CS, Dahi PB, Myskowski P, Kheterpal M, Dogan A, Pulitzer M, Tang L, Ni A, Horwitz SM (2016) A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-Cell lymphomas. Blood (ASH Annual Meeting Abstracts) 128:2991
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, Siddiqi T, Kennedy DA, Oki Y (2014) Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123:3095–3100
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR (2014) Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol 32:3137–3143
Delarue R, Dupuis J, Sujobert P, Barbieux S, Marçais A, Tournilhac O, Lachenal F, Cheminant M, Sarkozy C, Fataccioli V, Morschhauser F, Hermine O, Haioun C, Gaulard P, Lemonnier F (2016) Treatment with hypomethylating agent 5-Azacytidine induces sustained response in angioimmunoblastic T Cell lymphomas. Blood (ASH Annual Meeting Abstracts) 128:4164
Horwitz S, O’Connor O, Jurczak W, Van Hoof A, Hess G, Gasztonyi Z, Doorduijn J, Walewski J, Brown P, Vranovsky A, Sissolak G, Aurer I, Nacinovic A, Shustov A, Chawla S, Knoblauch P, Wulf G, Visser O, Zinzani P, Masszi T (2013) Belinostat in relapsed or refractory peripheral T-cell lymphoma subtype angioimmunoblastic T-cell lymphoma: results from the pivotal BELIEF trial. Hematol Oncol 31(Suppl. 1):147
Delarue R, Dupuis J, Sujobert P, Barbieux S, Marçais A, Tournilhac O, Lachenal F, Cheminant M, Sarkozy C, Fataccioli V, Morschhauser F, Hermine O, Haioun C, Gaulard P, Lemonnier F (2016) Treatment with hypomethylating agent 5-azacytidine induces sustained response in angioimmunoblastic T cell lymphomas
Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Bene MC, Martin A, Lamy T (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol Official J Am Soc Clin Oncol 31:104–110
Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21:860–863
Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R, Johnston J, Belch A, Reiman T (2010) Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116:4541–4548
Advani R, Horwitz S, Zelenetz A, Horning SJ (2007) Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leukemia Lymp 48:521–525
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Yabe, M., Dogan, A., Horwitz, S.M., Moskowitz, A.J. (2019). Angioimmunoblastic T-Cell Lymphoma. In: Querfeld, C., Zain, J., Rosen, S. (eds) T-Cell and NK-Cell Lymphomas. Cancer Treatment and Research, vol 176. Springer, Cham. https://doi.org/10.1007/978-3-319-99716-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-99716-2_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99715-5
Online ISBN: 978-3-319-99716-2
eBook Packages: MedicineMedicine (R0)